Stocks
Relmada Therapeutics, Inc.RLMD
NASDAQHealthcareBiotechnology$4.52-3.90%
Price as of · delayed, not real-time
Focused on developing novel therapies for central nervous system disorders, this biopharmaceutical company is advancing its lead product candidate for major depressive disorder. Investors closely monitor its clinical trial progress and potential market impact in the mental health treatment space.
Market Cap: $433.4M52W Range: $1.45-$8.00
Congressional Interest in Relmada Therapeutics, Inc. (RLMD)
1 member of Congress has disclosed 2 trades in Relmada Therapeutics, Inc. (RLMD), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 1 sale. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
2
Unique Politicians
1
Buys
1
Sells
1
Who in Congress Is Trading RLMD?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-12-12 | Christopher L. Jacobs | sell | $1K-$15K |
| 2022-11-08 | Christopher L. Jacobs | buy | $1K-$15K |